Alembic Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/blg8tcggqrz3mvi20dq0bdi6.pdf

Key Takeaways


U.S. Generics: The Bosutinib Quarter and Beyond

Pranav Amin: "So bosutinib has done, yes, far higher than expectations or what we expect. It's -- as you know, we have exclusivity till end of November. So we've got 2 more months, which will be October, November, we'll see. What happens after that, I don't know. Let's see what the market shapes up as."

India Branded: The Turnaround Thesis

Pranav Amin: "So over the next couple of quarters, we should be at IPM or higher."

U.S. Branded: Early Innings, Defined Cost

Pranav Amin: "I believe that we will start breaking even in the first half of next -- by the end of this year or the first half of next year is when we'll break even. But the trends are positive. I think we're seeing a month-on-month increase in the activities and prescriptions as well."

Margins: Expansion with Embedded Investment

G. Krishnan: "So I think you should look at the interplay how the gross margin to EBITDA is flowing through what we expect for the full year -- for the first half, we have about 22% EBITDA margins, which we expect to continue towards the second half as well. So we should expect the margin profile to hold for the rest of the year."

Capital Allocation and Returns


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth20% to 25% YoY (raised from mid-teens)FY27
U.S. business growthUp to 40% YoYFY27
API business growthAt least high teens YoYFY27
India branded growthAlign with market, reach IPM or higherNext 2–3 quarters
Acute segment recoveryReach IPM-level growthNext couple of quarters
Ex-U.S. markets growthMid-teensFY27
EBITDA margin~22% profile to holdH2 FY27
Gross marginRemain within 70–75% rangeOngoing
U.S. branded EBITDA dilution150–200 bpsFY27
U.S. branded breakevenBreakeven achievedEnd-FY27 to H1 FY28
U.S. generics launches>30 launches, ~25% FTF/day-1Next 18 months
DifGen collaboration contributionRevenue contribution beginsFY28
U.S. growth (normalized)Close to mid, about 10–12%FY28 (if launches pan out)
Medium-term EBITDA marginMove toward 20%FY28–FY29

Key Metrics

MetricQ2 FY27
Consolidated revenue₹2,603 crores, +36% YoY
India business growth14% YoY
Human Health growth11% YoY
Animal Health growth23% YoY
U.S. Generics revenue growth72% YoY
U.S. Generics base portfolio growth (ex-new launches)23% YoY
Ex-U.S. markets growth12% YoY
API business growth39% YoY, volume-led including certain CMO deliveries
Gross margin73.7%, expanded 70 bps YoY
R&D expenditure8% of revenue
EBITDA margin22.2%, expanded ~520 bps YoY from 17% in Q2 last year
Profit after tax₹335 crores, +81% YoY
Effective tax rate~24%, compared with 18% in previous year
Net debt₹1,236 crores, less than 1x full year EBITDA
H1 FY27 capex~₹250 crores
FY27 consolidated revenue growth guidance (raised)About 20% to 25%, up from mid-teens indicated last quarter
FY27 U.S. business growth guidance (raised)Up to 40% YoY for full year
FY27 API business growth guidance (raised)At least high teens for full year
U.S. branded contribution to total U.S. revenueClose to 3%
U.S. branded business full-year EBITDA dilution guidance150 to 200 bps
U.S. pipeline launches over next 18 monthsMore than 30, with around a quarter being FTF or shared day-1 opportunities
DifGen collaboration portfolio sizeOver 20 products, addressing aggregate U.S. reference market of ~$5 billion
U.S. branded field force30 to 35 reps currently, goal of 40 to 45
U.S. branded breakeven expectationBy end of FY27 or first half of FY28
FY28 U.S. growth expectationAbout 10% to 12% if all launches pan out well